An isolated antibody that binds to the IL-4 receptor, which comprises a light chain variable domain, where a. The light chain CDR1 comprises residues 24-35 of SEQ ID NO: 6 and b. The CDR2 light chain comprises residues 51-57 of SEQ ID NO: 6, and c. The CDR3 light chain comprises residues 90-99 of SEQ ID NO: 6 .； and a heavy chain variable domain, where the heavy chain sequences CDR1, CDR2 and CDR3 comprise residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 16, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 18, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 20, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 22, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 26, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 28, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 30, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID N032 , respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 34, respectively, residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 38, respectively or residues 30 to 35, 49 to 65 and 97 to 104 of SEQ ID NO: 40, respectively.Un anticuerpo aislado que se une al receptor de IL-4, que comprende un dominio variable de cadena ligera, donde a. la cadena ligera CDR1 comprende los residuos 24-35 de la SEC ID NO:6 y b. la cadena ligera CDR2 comprende los residuos 51-57 de la SEC ID NO:6, y c. la cadena ligera CDR3 comprende los residuos 90-99 de la SEC ID NO:6.； y un dominio variable de cadena pesada, donde las secuencias de la cadena pesada CDR1, CDR2 y CDR3 comprenden los residuos 30 a 35, 49 a 65 y 97 a 104 de la SEC ID NO:16, respectivamente, los residuos 30 a 35, 49 a 65 y 97 a 104 de la SEC ID NO:18, respectivamente, los residuos 30 a 35, 49 a 65 y 97 a 104 de la SEC ID NO: 20, respectivamente, los residuos 30 a 35, 49 a 65 y 97 a 104 de la SEC ID NO:22, respectivamente, los residuos 30 a
